English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17918/22935 (78%)
Visitors : 6791522      Online Users : 164
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/22197


    Title: Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV
    Authors: Yu-Lin Lee;Kuan-Yin Lin;Shu-Hsing Cheng;Po-Liang Lu;Ning-Chi Wang;Mao-Wang Ho;Chia-Jui Yang;Bo-Huang Liou;Hung-Jen Tang;Shie-Shian Huang;Sung-Hsi Huang;Tun-Chieh Chen;Chi-Ying Lin;Shih-Ping Lin;Yuan-Ti Lee;Chien-Ching Hung;Taiwan HIV Study Group
    Contributors: 中山醫學大學;醫研所
    Keywords: Integrase strand transfer inhibitor;Two-drug regimen;Antiretroviral resistance;Weight gain;Dyslipidaemia
    Date: 2021-07-18
    Issue Date: 2022-03-29T02:44:06Z (UTC)
    Publisher: Elsevier B.V.
    Abstract: Real-world experience with dolutegravir (DTG) plus boosted protease inhibitor (bPI) as a two-drug regimen is limited for highly experienced HIV-positive patients with virological failure or intolerance to antiretroviral therapy. Patients receiving DTG plus bPI between September 2016 and June 2019 at 15 designated hospitals for HIV care in Taiwan were retrospectively included in this study. A standardised case record form was used to collect clinical data. The primary endpoint was virological response, defined as achieving or maintaining plasma HIV-RNA <50 copies/mL at Week 48. A total of 77 patients were included; 58 (75.3%) had documented genotypic resistance to 1–4 antiretroviral classes. The most commonly used PI was darunavir (87.0%; 67/77). Seven patients (9.1%) had no virological data at Week 48, including three with loss to follow-up, one severe hyperlipidaemia, one renal failure and cardiovascular disease, one superimposed HBV infection and one death from anal cancer. The virological response rate increased from 59.7% at baseline to 90.9% at Week 24 and 85.7% at Week 48. The only patient (1.3%) with virological failure at Week 48 had poor adherence and baseline low-level resistance to darunavir with resistance-associated mutations at M46L, I50V and V82A. Compared with baseline, mean total cholesterol increased by 20.1 mg/dL and weight by 2.8 kg at Week 48, while the estimated glomerular filtration rate decreased by 14.4 mL/min/1.73m2 (both P < 0.05). We conclude that a two-drug regimen containing DTG plus bPI was effective in highly-experienced HIV-positive patients, but metabolic impact and weight gain should be closely monitored.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/22197
    Relation: Int J Antimicrob Agents, 58(3), 106403.
    Appears in Collections:[醫學研究所] 期刊論文

    Files in This Item:

    File Description SizeFormat
    1-s2.0-S0924857921001680-main.pdf683KbAdobe PDF117View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback